<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04039256</url>
  </required_header>
  <id_info>
    <org_study_id>RJH-20190728</org_study_id>
    <nct_id>NCT04039256</nct_id>
  </id_info>
  <brief_title>Phase II Clinical Trial of Percutaneous Ventricular Restoration Using Heartech® Device Preventing Heart Failure Post Myocardial Infarction (The Partical Study)</brief_title>
  <acronym>Partical</acronym>
  <official_title>Efficacy And Safty of Heartech® Left Ventricular Partitioning Device In Treating Heart Failure Post Myocardial Infarction (Phase II Clinical Trial: The Partical Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multi-center, single-group, target-value clinical study. The primary
      safety end points are major adverse cardiovascular events (MACCE) 30 days after device
      implantation.

      The primary efficacy end point is the end of left ventricular systolic volume index (LVESVI)
      reduction at 6 month.

      The secondary observational end points includes immediate success rate of the procedure,
      all-cause mortality, cardiac death, rehospitalization rates and MACCE occurrence rate within
      12 month. Besides, left ventricular end systolic volume index (LVESVI) change at 30 days,12
      months, left ventricular ejection fraction (LVEF), left ventricular end-diastolic volume
      index (LVEDVI), 6 minutes walk test, heart function evaluation (NYHA classification) and
      quality of life (EQ-5D) at 30 days, 6 months, 12 months will also be evaluated.

      After statistical hypothesis and sample size estimation, the sample size of this clinical
      trial was 117 cases. All subjects were followed up 30 days, 6 months and 12 months after
      implantation of the Heartech® left ventricular partitioning device. All relevant clinical
      data were managed by professional data management center, and all relevant clinical data were
      statistically analyzed by third-party statistical center.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      MACCE includes all-cause death, myocardial infarction, stroke and any elective or emergency
      cardiac or thoracic aortic surgery or catheter-based interventional therapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2, 2020</start_date>
  <completion_date type="Anticipated">July 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of MACCE [primary safety]</measure>
    <time_frame>30 days</time_frame>
    <description>major adverse cardiovascular events (MACCE)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>LVESVi Reduction [primary efficacy]</measure>
    <time_frame>6 month</time_frame>
    <description>left ventricular systolic volume index (LVESVi) reduction</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Procedure Success</measure>
    <time_frame>immediate</time_frame>
    <description>success rate of the procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>12 month</time_frame>
    <description>all-cause mortality rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death</measure>
    <time_frame>12 month</time_frame>
    <description>cardiac death rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rehospitalization</measure>
    <time_frame>12 month</time_frame>
    <description>rehospitalization rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of MACCE</measure>
    <time_frame>12 month</time_frame>
    <description>MACCE occurrence rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LVESVi Reduction</measure>
    <time_frame>12 month</time_frame>
    <description>left ventricular end systolic volume index (LVESVi) change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LVEDVi Reduction</measure>
    <time_frame>12 month</time_frame>
    <description>left ventricular end-diastolic volume index (LVEDVi)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LVEF change</measure>
    <time_frame>12 month</time_frame>
    <description>left ventricular ejection fraction (LVEF) detected by echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac function</measure>
    <time_frame>12 month</time_frame>
    <description>cardiac function evaluation (NYHA classification)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Walk tolerance</measure>
    <time_frame>12 month</time_frame>
    <description>6 minutes walk test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>life quality</measure>
    <time_frame>12 month</time_frame>
    <description>quality of life (EQ-5D)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">117</enrollment>
  <condition>Efficacy, Safty, Device</condition>
  <arm_group>
    <arm_group_label>PVR implantation group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients enrolled receive PVR intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>percutaneous ventricular restoration using heartech® device</intervention_name>
    <description>Patients who are confirmed suitability by imaging analysis, receive heartech® left ventricular partitioning device implantation.</description>
    <arm_group_label>PVR implantation group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI&lt;40;

          -  left ventricular ejection fraction ≤45% and ≥20%;

          -  patients with left ventricular end-systolic volume index (ESVI) ≥50mL/m2;

          -  transthoracic ultrasound showed contradictory motion of the left ventricle after
             myocardial infarction;

          -  60 days prior to anterior wall myocardial infarction with ischemic heart failure (NYHA
             grade II to &quot;not hospitalized&quot; grade IV);

          -  the left ventricle must have the appropriate anatomic structure (size and shape) which
             is confirmed by cardiac CT and left ventricular angiography to implant the appropriate
             Heartech® device;

          -  agree to receive reasonable treatment according to current ACC/AHA and Chinese
             guidelines for heart failure diagnosis and treatment;

          -  the subjects or their legal representatives are informed of the nature of this study
             and agree to participate in all the terms of this study, sign the informed consent
             approved by the ethics committee, agree to accept the postoperative treatment plan and
             follow-up requirements, and can complete the examination of follow-up.

        Exclusion Criteria:

          -  patients whose left ventricular anatomy is not suitable for Heartech® occlusal device
             implantation;

          -  the abnormal ventricular wall movement not contains the anterior wall of the left
             ventricle, the apex of the left ventricle and the ventricular septum;

          -  patients with thrombosis in the left ventricle;

          -  mitral stenosis or regurgitation (tricuspid, aortic or mitral) &gt; 2+ (moderate);

          -  recent (within 6 month) cerebrovascular accident (CVA) or transient ischemic attack
             (TIA);

          -  end-stage renal disease requiring long-term dialysis, episodic sepsis or active phase
             endocarditis;

          -  life expectancy at admission &lt; 1 year;

          -  known allergy to aspirin, heparin, warfarin, Nitinol (alloys of titanium and nickel)
             or contraindications, or sensitivity to contrast agents;

          -  cardiogenic shock occurred within 72 hours before procedure;

          -  pregnancy or planned pregnancy during the study period;

          -  participated in clinical trials of other drugs or medical devices during the same
             period;

          -  the researcher judged that the patient had poor compliance and could not complete the
             study as required;

          -  other conditions considered unsuitable for participation in this clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fenghua Ding, MD. Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Cardiovascular research instittion, Shanghai Jiao Tong University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhengbin Zhu, M.D Ph.D.</last_name>
    <phone>021-64370045</phone>
    <phone_ext>673344</phone_ext>
    <email>zzb11561@rhj.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ruijin Hospital, Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruiyan Zhang, MD.</last_name>
      <phone>86-21-64370045</phone>
      <phone_ext>665215</phone_ext>
      <email>zhangruiyan@263.net</email>
    </contact>
    <contact_backup>
      <last_name>Zhengbin Zhu, MD.</last_name>
      <phone>86-21-64370045</phone>
      <phone_ext>665380</phone_ext>
      <email>gemini198306@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ruiyan Zhang, MD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Zhu Z, Yu J, Xu K, Tang Y, Fang Y, Gu J, Gu S, Ding F, Modine T, Zhang R. First-in-man study of Heartech® percutaneous left ventricular partitioning device for treatment of heart failure postmyocardial infarction. Catheter Cardiovasc Interv. 2019 Nov 15;94(6):845-853. doi: 10.1002/ccd.28366. Epub 2019 Jun 23.</citation>
    <PMID>31231944</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>July 28, 2019</study_first_submitted>
  <study_first_submitted_qc>July 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2019</study_first_posted>
  <last_update_submitted>January 9, 2020</last_update_submitted>
  <last_update_submitted_qc>January 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Zhang Qi, MD</investigator_full_name>
    <investigator_title>Chief of Cardiology Department, Rui Jin Hospital</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

